{"id":4614,"date":"2016-05-31T06:18:03","date_gmt":"2016-05-31T06:18:03","guid":{"rendered":"https:\/\/jurmed.ro\/pacienti\/?p=4614"},"modified":"2016-05-31T06:18:03","modified_gmt":"2016-05-31T06:18:03","slug":"comunicat-de-presa","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/","title":{"rendered":"Comunicat de pres\u0103"},"content":{"rendered":"<p><a href=\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2016\/05\/Prof.-Dr.-Florinel-B\u0103dulescu-pres.-Societatea-Na\u021bional\u0103-de-Oncologie-Medical\u0103-Rom\u00e2nia-Oana-Costan-CNAS-si-Cezar-Irimia-presedinte-FABC.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-4615\" src=\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2016\/05\/Prof.-Dr.-Florinel-B\u0103dulescu-pres.-Societatea-Na\u021bional\u0103-de-Oncologie-Medical\u0103-Rom\u00e2nia-Oana-Costan-CNAS-si-Cezar-Irimia-presedinte-FABC-300x200.jpg\" alt=\"????????????????????????????????????\" width=\"300\" height=\"200\" srcset=\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2016\/05\/Prof.-Dr.-Florinel-B\u0103dulescu-pres.-Societatea-Na\u021bional\u0103-de-Oncologie-Medical\u0103-Rom\u00e2nia-Oana-Costan-CNAS-si-Cezar-Irimia-presedinte-FABC-300x200.jpg 300w, https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2016\/05\/Prof.-Dr.-Florinel-B\u0103dulescu-pres.-Societatea-Na\u021bional\u0103-de-Oncologie-Medical\u0103-Rom\u00e2nia-Oana-Costan-CNAS-si-Cezar-Irimia-presedinte-FABC-768x511.jpg 768w, https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2016\/05\/Prof.-Dr.-Florinel-B\u0103dulescu-pres.-Societatea-Na\u021bional\u0103-de-Oncologie-Medical\u0103-Rom\u00e2nia-Oana-Costan-CNAS-si-Cezar-Irimia-presedinte-FABC.jpg 986w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<h2>Studiu InoMed-IMAS: 5,2% dintre rom\u00e2ni au fost diagnostica\u021bi cu cancer, la un moment dat, de-a lungul vie\u021bii<\/h2>\n<ul>\n<li><em>21,1% dintre rom<\/em><em>\u00e2<\/em><em>ni au\/au avut cel pu<\/em><em>\u021b<\/em><em>in un membru din familia restr<\/em><em>\u00e2<\/em><em>ns<\/em><em>\u0103 <\/em><em>(so<\/em><em>\u021b<\/em><em>ul\/so<\/em><em>\u021b<\/em><em>ia, fiul\/fiica, mama\/tata) diagnosticat cu cancer<\/em><\/li>\n<li><em>numai 1% dintre rom<\/em><em>\u00e2<\/em><em>ni consider<\/em><em>\u0103 <\/em><em>c<\/em><em>\u0103 <\/em><em>autorit<\/em><em>\u0103\u021b<\/em><em>ile reprezint<\/em><em>\u0103 <\/em><em>principalul sprijin <\/em><em>\u00ee<\/em><em>n cazul ar fi diagnostica<\/em><em>\u021b<\/em><em>i cu cancer<\/em><\/li>\n<li><em>75% dintre rom<\/em><em>\u00e2<\/em><em>ni consider<\/em><em>\u0103 <\/em><em>c<\/em><em>\u0103 <\/em><em>dureaz<\/em><em>\u0103 <\/em><em>prea mult p<\/em><em>\u00e2<\/em><em>n<\/em><em>\u0103 <\/em><em>un medicament nou descoperit s<\/em><em>\u0103 <\/em><em>ajung<\/em><em>\u0103 <\/em><em>la pacien<\/em><em>\u021b<\/em><em>ii cu cancer din Rom<\/em><em>\u00e2<\/em><em>nia<\/em><\/li>\n<\/ul>\n<p><strong>Bucure<\/strong><strong>\u0219<\/strong><strong>ti, 30 mai 2016<\/strong> &#8211; Centrul pentru Inova\u021bie \u00een Medicin\u0103 (InoMed) \u0219i compania specializat\u0103 \u00een studii de pia\u021b\u0103 IMAS au realizat prima cercetare sociologic\u0103 reprezentativ\u0103 la nivel na\u021bional care \u0219i-a propus s\u0103 evalueze rela\u021bia dintre rom\u00e2ni \u0219i cancer. Datele au fost colectate \u00een perioada 1-20 aprilie 2016, pe un e\u0219antion reprezentativ la nivel na\u021bional.<\/p>\n<p>\u201cCentrul pentru Inova\u021bie \u00een Medicin\u0103, prin rezultatele prezentului studiu, a demonstrat c\u0103 resursele Societ\u0103\u021bii Civile \u00een materie de servicii medicale sunt foarte mari \u0219i, cu siguran\u021b\u0103, ar trebui folosite \u0219i de c\u0103tre Autorit\u0103\u021bi. Domnul dr. Marius Geant\u0103, cel care a venit cu ini\u021biativa studiului, este de altfel unul dintre pu\u021binii medici din Rom\u00e2nia cu responsabilitate medical\u0103, social\u0103 \u0219i uman\u0103\u201d, a declarat domnul Alin Teodorescu, pre\u0219edintele IMAS.<\/p>\n<h3>Team\u0103 crescut\u0103 fa\u021b\u0103 de cancer<\/h3>\n<p>Rezultatele studiului indic\u0103 faptul c\u0103 <strong>un rom<\/strong><strong>\u00e2<\/strong><strong>n din 4 are o experien<\/strong><strong>\u021b\u0103<\/strong> <strong>cu cancerul<\/strong>:<\/p>\n<ul>\n<li>5,2% afirm\u0103 c\u0103 au fost diagnostica\u021bi cu o form\u0103 de cancer, ceea ce corespunde unui num\u0103r total de aproximativ 840.000 de persoane.<\/li>\n<li>21,1% au\/au avut un membru al familiei (so\u021bul\/so\u021bia, fiul\/fiica, mama\/tata) diagnosticat cu cancer la un moment dat, ceea ce corespunde unui num\u0103r total de 3,34 milioane de rom\u00e2ni<\/li>\n<\/ul>\n<p>\u00cen ceea ce prive\u0219te percep\u021bia asupra bolii, 45% dintre cei care au r\u0103spuns consider\u0103 c\u0103 diagnosticul de cancer duce \u00eentotdeauna la deces.<\/p>\n<p>Principala temere legat\u0103 de cancer este c\u0103 nu poate fi vindecat (26,6%), la care se adaug\u0103 lipsa tratamentelor eficiente (7,4%), indisponibilitatea tratamentelor \u00een Rom\u00e2nia (7,1), lipsa banilor necesari pentru tratamente (5,8), plus teama de boala \u00een sine, cu tot ce presupune ea (7,6%).<\/p>\n<p>\u201cDac\u0103, \u00een urm\u0103 cu 30 de ani, diagnosticul de cancer era sinonim cu sf\u00e2r\u0219itul iminent, \u00eentr-un orizont de timp foarte limitat, acum lucrurile s-au schimbat esen\u021bial. Multe forme de cancer sunt acum boli cronice, precum diabetul zaharat sau poliartrita reumatoid\u0103. <strong>2 din 3 pacien<\/strong><strong>\u021b<\/strong><strong>i cu cancer diagnostica<\/strong><strong>\u021b<\/strong><strong>i <\/strong><strong>\u00ee<\/strong><strong>n SUA tr<\/strong><strong>\u0103<\/strong><strong>iesc la 5 ani de la primirea diagnosticului. Sunt descrise cazuri de supravie<\/strong><strong>\u021b<\/strong><strong>uiri de lung<\/strong><strong>\u0103<\/strong> <strong>durat<\/strong><strong>\u0103<\/strong><strong>, de peste 10 ani, la pacien<\/strong><strong>\u021b<\/strong><strong>i care au primit diagnosticul de melanom malign metastatic nerezecabil, dar care au avut <\/strong><strong>\u0219<\/strong><strong>ansa de a fi trata<\/strong><strong>\u021b<\/strong><strong>i cu terapii personalizate <\/strong><strong>\u0219<\/strong><strong>i cu imunoterapii<\/strong>\u201d, spune dr. Marius Geant\u0103, pre\u0219edinte al Centrului pentru Inova\u021bie \u00een Medicin\u0103 (InoMed).<\/p>\n<p>\u201c\u00cen ciuda acestui progres remarcabil din punct de vedere \u0219tiin\u021bific, rom\u00e2nii \u00eenc\u0103 asociaz\u0103 \u00eentr-o propor\u021bie considerabil\u0103 diagnosticul de cancer cu iminen\u021ba decesului, pe fondul unui acces redus la mijloacele moderne de preven\u021bie, screening, diagnostic \u0219i tratament, dar \u0219i pe fondul unui nivel redus de informare asupra evolu\u021biilor spectaculoase din domeniul oncologiei, din ultimele decade\u201d.<\/p>\n<h3>Statul: cote reduse de \u00eencredere \u0219i astept\u0103ri limitate<\/h3>\n<p>65% dintre rom\u00e2ni, indiferent dac\u0103 au fost sau nu diagnostica\u021bi cu cancer, consider\u0103 c\u0103 statul rom\u00e2n nu asigur\u0103 un tratament corespunz\u0103tor pentru pacien\u021bii cu cancer. \u00cen acela\u0219i timp, 75% dintre rom\u00e2ni consider\u0103 c\u0103 dureaz\u0103 prea mult ca un medicament nou descoperit s\u0103 ajung\u0103 la pacien\u021bii din Rom\u00e2nia.<\/p>\n<p>\u201c\u00cen acest moment, <strong>pacien<\/strong><strong>\u021b<\/strong><strong>ii rom<\/strong><strong>\u00e2<\/strong><strong>ni cu cancer au acces gratuit la mai pu<\/strong><strong>\u021b<\/strong><strong>in de 15% dintre medicamentele aprobate, <\/strong><strong>\u00ee<\/strong><strong>n perioada 2006-2015, de Agen<\/strong><strong>\u021b<\/strong><strong>ia European<\/strong><strong>\u0103<\/strong> <strong>a Medicamentulu<\/strong>i\u201d, declar\u0103 dr. Marius Geant\u0103, pre\u0219edintele Centrului pentru Inova\u021bie \u00een Medicin\u0103 (InoMed).<\/p>\n<p>Rom\u00e2nii consider\u0103 c\u0103 principalul sprijin \u00een lupta cu cancerul este familia (46,3%), urmat\u0103 de noile tehnologii (inclusiv medicamentele \u0219i echipamentele medicale de ultim\u0103 genera\u021bie, 30,1%) \u0219i de medici (16,5%), \u00een timp ce numai 1% consider\u0103 c\u0103 autorit\u0103\u021bile reprezint\u0103 principalul sprijin \u00een cazul unui diagnostic de cancer.<\/p>\n<p>\u201cMinisterul S\u0103n\u0103t\u0103\u021bii are o cot\u0103 de \u00eencredere de numai 39% \u0219i doar spitalele publice se afl\u0103 mai jos \u00een acest clasament (35%), cu men\u021biunea c\u0103 datele au fost colectate \u00eenainte de criza dezinfectan\u021bilor. La polul opus, se afl\u0103 \u00eencrederea \u00een medici, <strong>66% dintre rom<\/strong><strong>\u00e2<\/strong><strong>ni afirm<\/strong><strong>\u00e2<\/strong><strong>nd c<\/strong><strong>\u0103<\/strong> <strong>au <\/strong><strong>\u00ee<\/strong><strong>ncredere mare <\/strong><strong>\u0219<\/strong><strong>i foarte mare <\/strong><strong>\u00ee<\/strong><strong>n doctori. Un alt aspect important relevat de studiu este c<\/strong><strong>\u0103<\/strong> <strong>9 din 10 pacien<\/strong><strong>\u021b<\/strong><strong>i cu cancer se declar<\/strong><strong>\u0103<\/strong> <strong>mul<\/strong><strong>\u021b<\/strong><strong>umi<\/strong><strong>\u021b<\/strong><strong>i de medicul oncolog curant<\/strong>\u201d, afirm\u0103 dr. Marius Geant\u0103.<\/p>\n<h3>Rat\u0103 redus\u0103 de penetrare a informa\u021biei despre inova\u021bia \u00een oncologie<\/h3>\n<p><strong>\u00ce<\/strong><strong>n Uniunea European<\/strong><strong>\u0103<\/strong><strong>, anul trecut, au fost aprobate 14 medicamente noi <\/strong><strong>\u00ee<\/strong><strong>mpotriva cancerului, fiind cel mai mare num<\/strong><strong>\u0103<\/strong><strong>r de molecule noi aprobate <\/strong><strong>\u00ee<\/strong><strong>n oncologie <\/strong><strong>\u00ee<\/strong><strong>ntr-un an, din istoria Agen<\/strong><strong>\u021b<\/strong><strong>iei Europene a Medicamentului.<\/strong><\/p>\n<p>\u201cCu toate acestea, doar 1,6% dintre cei care au r\u0103spuns au indicat intervalul corect, aspect care arat\u0103 un nivel redus al penetr\u0103rii informa\u021biei despre inova\u021bia \u00een oncologie, la nivelul popula\u021biei Rom\u00e2niei, dar \u0219i un orizont de a\u0219teptare limitat \u00een privin\u021ba terapiilor noi, inovatoare, destinate cancerului. <strong>Mul<\/strong><strong>\u021b<\/strong><strong>i rom<\/strong><strong>\u00e2<\/strong><strong>ni pur <\/strong><strong>\u0219<\/strong><strong>i simplu nu <\/strong><strong>\u0219<\/strong><strong>tiu <\/strong><strong>\u0219<\/strong><strong>i nu cred c<\/strong><strong>\u0103<\/strong> <strong>dinamica dezvolt<\/strong><strong>\u0103<\/strong><strong>rii medicamentelor <\/strong><strong>\u00ee<\/strong><strong>n cancer este at<\/strong><strong>\u00e2<\/strong><strong>t de intens<\/strong><strong>\u0103<\/strong> <strong>\u0219<\/strong><strong>i <\/strong><strong>\u00ee<\/strong><strong>n fiecare an se aprob<\/strong><strong>\u0103<\/strong> <strong>medicamente personalizate sau imunoterapii care au poten<\/strong><strong>\u021b<\/strong><strong>ialul de a schimba destinul unui pacient cu cancer<\/strong>\u201d, explic\u0103 dr. Marius Geant\u0103.<\/p>\n<p>\u201cDe\u0219i 84,8% sunt de acord c\u0103 acela\u0219i tratament \u00eempotriva cancerului poate avea rezultate foarte diferite la pacien\u021bi cu diagnostic similar, doar pu\u021bin peste jum\u0103tate intre rom\u00e2ni afirm\u0103 c\u0103 \u0219i-ar dori un tratament personalizat, aspect relevant pentru nevoia de a implementa programe de informare \u0219i educare menite s\u0103 creasc\u0103 nivelul de \u00een\u021belegere asupra bolii \u0219i a tratamentelor moderne, precum medicina personalizat\u0103 sau imuno-oncologia. Cu c\u00e2t un pacient sau un cet\u0103\u021bean este mai informat asupra inova\u021biei \u00een oncologie, cu at\u00e2t este mai \u00een m\u0103sur\u0103 s\u0103-\u0219i cear\u0103 drepturile \u0219i s\u0103 impulsioneze autorit\u0103\u021bile pentru a asigura un acces continuu, extins \u0219i cost-eficient la inova\u021bia \u00een oncologie\u201d, afirm\u0103 dr. Marius Geant\u0103.<\/p>\n<h3>Inova\u021bia pe care rom\u00e2nii nu \u0219i-o pot permite<\/h3>\n<p><strong>Mai mult de o treime dintre rom<\/strong><strong>\u00e2<\/strong><strong>ni au auzit de concepte <\/strong><strong>\u0219<\/strong><strong>tiin<\/strong><strong>\u021b<\/strong><strong>ifice revolu<\/strong><strong>\u021b<\/strong><strong>ionare, dar care sunt deja parte din realitatea terapeutic<\/strong><strong>\u0103<\/strong> <strong>actual<\/strong><strong>\u0103<\/strong> <strong>din oncologie, precum medicina personalizat<\/strong><strong>\u0103<\/strong> <strong>\u0219<\/strong><strong>i imuno-oncologia.<\/strong> Aceste terapii sunt asociate, de c\u0103tre responden\u021bi, cu costuri crescute, a\u0219a \u00eenc\u00e2t <strong>doar 16% afirm<\/strong><strong>\u0103<\/strong> <strong>c<\/strong><strong>\u0103<\/strong> <strong>\u0219<\/strong><strong>i-ar putea permite cu u<\/strong><strong>\u0219<\/strong><strong>urin<\/strong><strong>\u021b\u0103<\/strong> <strong>s<\/strong><strong>\u0103<\/strong> <strong>acopere costurile tratamentelor moderne pentru cancer, <\/strong><strong>\u00ee<\/strong><strong>n timp de 44% nu v<\/strong><strong>\u0103<\/strong><strong>d posibilitatea efectu<\/strong><strong>\u0103<\/strong><strong>rii pl<\/strong><strong>\u0103\u021b<\/strong><strong>ilor necesare pentru un tratament inovativ. <\/strong><\/p>\n<p>\u201cDatele confirm\u0103 \u00eenc\u0103 odat\u0103 rolul marcant pe care statul ar trebui s\u0103-l joace \u00een asigurarea accesului pacientului cu cancer la cel mai \u00eenalt nivel de asisten\u021b\u0103 medical\u0103. <strong>\u00ce<\/strong><strong>n afar<\/strong><strong>\u0103<\/strong> <strong>de compensarea medicamentelor noi, o alt<\/strong><strong>\u0103<\/strong> <strong>posibilitate de a asigura un acces rapid la inova<\/strong><strong>\u021b<\/strong><strong>ie, f<\/strong><strong>\u0103<\/strong><strong>r<\/strong><strong>\u0103<\/strong> <strong>costuri din partea statului, este stimularea particip<\/strong><strong>\u0103<\/strong><strong>rii <\/strong><strong>\u00ee<\/strong><strong>n studii clinice<\/strong>\u201d, explic\u0103 dr. Marius Geant\u0103, pre\u0219edintele Centrului pentru Inova\u021bie \u00een Medicin\u0103 (InoMed).<\/p>\n<p>Numai c\u0103 doar 6% dintre pacien\u021bii cu cancer din Rom\u00e2nia declar\u0103 c\u0103 au luat parte la studii clinice cu medicamentele oncologice, pe fondul unui procent de 53% din popula\u021bie care consider\u0103 c\u0103 intrarea \u00eentr-un studiu clinic ofer\u0103 acces la tratamente de ultim\u0103 or\u0103, mai bune dec\u00e2t cele existente.<\/p>\n<p>\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014\u2014<\/p>\n<p><em>Studiul InoMed &#8211; IMAS este parte a programului Oncology Innovation Agenda, derulat de Centrul pentru Inova<\/em><em>\u021b<\/em><em>ie <\/em><em>\u00ee<\/em><em>n Medicin<\/em><em>\u0103<\/em> <em>\u00ee<\/em><em>n anul 2016. <\/em><\/p>\n<p><em>Partenerii programului Oncology Innovation Agenda sunt companiile BMS, MSD <\/em><em>\u0219<\/em><em>i Roche.<\/em><\/p>\n<p><em>Centrul pentru Inova<\/em><em>\u021b<\/em><em>ie <\/em><em>\u00ee<\/em><em>n Medicin<\/em><em>\u0103<\/em> <em>este o asocia<\/em><em>\u021b<\/em><em>ie non-guvernamental<\/em><em>\u0103<\/em><em>, <\/em><em>\u00ee<\/em><em>nfiin<\/em><em>\u021b<\/em><em>at<\/em><em>\u0103<\/em> <em>\u00ee<\/em><em>n anul 2014, cu scopul de a aduce inova<\/em><em>\u021b<\/em><em>ia <\/em><em>\u00ee<\/em><em>n medicin<\/em><em>\u0103<\/em> <em>pe agenda public<\/em><em>\u0103<\/em> <em>din Rom<\/em><em>\u00e2<\/em><em>nia, <\/em><em>\u00ee<\/em><em>n beneficiul oamenilor.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Studiu InoMed-IMAS: 5,2% dintre rom\u00e2ni au fost diagnostica\u021bi cu cancer, la un moment dat, de-a lungul vie\u021bii 21,1% dintre rom\u00e2ni au\/au avut cel pu\u021bin un membru din familia restr\u00e2ns\u0103 (so\u021bul\/so\u021bia, [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4614","post","type-post","status-publish","format-standard","category-stiri-noutati"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comunicat de pres\u0103 - Jurmed - Pacienti<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comunicat de pres\u0103 - Jurmed - Pacienti\" \/>\n<meta property=\"og:description\" content=\"Studiu InoMed-IMAS: 5,2% dintre rom\u00e2ni au fost diagnostica\u021bi cu cancer, la un moment dat, de-a lungul vie\u021bii 21,1% dintre rom\u00e2ni au\/au avut cel pu\u021bin un membru din familia restr\u00e2ns\u0103 (so\u021bul\/so\u021bia, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Pacienti\" \/>\n<meta property=\"article:published_time\" content=\"2016-05-31T06:18:03+00:00\" \/>\n<meta name=\"author\" content=\"costelv\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"costelv\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\"},\"author\":{\"name\":\"costelv\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"headline\":\"Comunicat de pres\u0103\",\"datePublished\":\"2016-05-31T06:18:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\"},\"wordCount\":1314,\"commentCount\":0,\"articleSection\":[\"Stiri \/ Noutati\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\",\"name\":\"Comunicat de pres\u0103 - Jurmed - Pacienti\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\"},\"datePublished\":\"2016-05-31T06:18:03+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\"},\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/pacienti\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comunicat de pres\u0103\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/\",\"name\":\"Jurmed - Pacienti\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d\",\"name\":\"costelv\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g\",\"caption\":\"costelv\"},\"url\":\"https:\/\/jurmed.ro\/pacienti\/author\/costelvoicu\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comunicat de pres\u0103 - Jurmed - Pacienti","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/","og_locale":"ro_RO","og_type":"article","og_title":"Comunicat de pres\u0103 - Jurmed - Pacienti","og_description":"Studiu InoMed-IMAS: 5,2% dintre rom\u00e2ni au fost diagnostica\u021bi cu cancer, la un moment dat, de-a lungul vie\u021bii 21,1% dintre rom\u00e2ni au\/au avut cel pu\u021bin un membru din familia restr\u00e2ns\u0103 (so\u021bul\/so\u021bia, [&hellip;]","og_url":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/","og_site_name":"Jurmed - Pacienti","article_published_time":"2016-05-31T06:18:03+00:00","author":"costelv","twitter_misc":{"Scris de":"costelv","Timp estimat pentru citire":"7 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/"},"author":{"name":"costelv","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"headline":"Comunicat de pres\u0103","datePublished":"2016-05-31T06:18:03+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/"},"wordCount":1314,"commentCount":0,"articleSection":["Stiri \/ Noutati"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/","url":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/","name":"Comunicat de pres\u0103 - Jurmed - Pacienti","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/#website"},"datePublished":"2016-05-31T06:18:03+00:00","author":{"@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d"},"breadcrumb":{"@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/pacienti\/comunicat-de-presa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/pacienti\/"},{"@type":"ListItem","position":2,"name":"Comunicat de pres\u0103"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/pacienti\/#website","url":"https:\/\/jurmed.ro\/pacienti\/","name":"Jurmed - Pacienti","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/d32bd0fe3243bb12082045e5e5635d2d","name":"costelv","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/562bbd538aef9094eff6466c34ed9504fe82c1cb144e421d853e80c3b3d5a9f8?s=96&r=g","caption":"costelv"},"url":"https:\/\/jurmed.ro\/pacienti\/author\/costelvoicu\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/4614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/comments?post=4614"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/4614\/revisions"}],"predecessor-version":[{"id":4616,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/4614\/revisions\/4616"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/media?parent=4614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/categories?post=4614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/tags?post=4614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}